Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy

American Journal of Cardiology

Volumn 96, Issue 10, 2005, Pages 1449-1451

  Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Papaioakeim, Miltiadis ^a   Hatzinikolaou, Eleni I ^a   Stakos, Dimitrios A ^a   Tentes, Ioannis K ^a   Papanas, Nikolaos ^a   Kortsaris, Alexandros ^a   Maltezos, Efstratios ^a   Hatseras, Dimitrios I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE A; NITRATE; SPIRONOLACTONE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; CARDIOMYOPATHY, DILATED; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 27644531500     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.06.096     Document Type: Article

References (24)

1. E.M. Wilson, H.R. Gunasinghe, M.L. Coker, P. Sprunger, D. Lee-Jackson, B. Bozkurt, A. Deswal, D.L. Mann, F.G. Spinale Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure J Card Fail 8 2002 390 398
2. T. Yamazaki, J.D. Lee, H. Shimizu, H. Uzui, T. Ueda Circulating matrix metalloproteinase-2 is elevated in patients with heart failure Eur J Heart Fail 6 2004 41 45
3. B. Schwartzkopff, M. Fassbach, B. Pelzer, M. Brehm, B.E. Strauer Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy Eur J Heart Fail 4 2002 439 444
4. F.G. Spinale, M.L. Coker, L.J. Heung, B.R. Bond, H.R. Gunashinghe, T. Etoh, A.T. Goldberg, J.L. Zellner, J. Crumbley A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
5. R.T. Lee Matrix metalloproteinase inhibition and the prevention of heart failure Trends Cardiovasc Med 11 2001 202 205
6. M.D. Cheitlin, J.S. Alpert, W.F. Armstrong, G.P. Aurigemma, G.A. Beller, F.Z. Bierman, T.W. Davidson, J.L. Davis, P.S. Douglas, L.D. Gillam ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography) Circulation 95 1997 1686 1744
7. P. Richardson, W. McKenna, M. Bristow, B. Maisch, B. Mautner, J. O'Connell, E. Olsen, G. Thiene, J. Goodwin, I. Gyarfas Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies Circulation 93 1996 841 842
8. C.P. Cannon, A. Battler, R.G. Brindis, J.L. Cox, S.G. Ellis, N.R. Every, J.T. Flaherty, R.A. Harrington, H.M. Krumholz, M.L. Simons ACC clinical data standards. American College of Cardiology key data elements and definition for measuring the clinical management and outcomes of patients with acute coronary syndromes J Am Coll Cardiol 38 2001 2114 2130
9. D. Reinhardt, H.H. Sigusch, J. Hensse, S.C. Tyagi, R. Korfer, H.R. Figulla Cardiac remodeling in end stage heart failure upregulation of MMP irrespective of the underlying disease and evidence for a direct inhibitory effect of ACE inhibitors on MMP Heart 88 2002 525 530
10. P. Rouet-Benzineb, J.M. Buhler, P. Dreyfus, A. Delcourt, R. Dorent, J. Perennec, B. Crozatier, A. Harf, C. Lafuma Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy potential role of MMP-9 in myosin-heavy chain degradation Eur J Heart Fail 1 1999 337 352
11. Y.Y. Li, A.M. Feldman, Y. Sun, C.F. McTiernan Differential expression of tissue inhibitors of metalloproteinases in the failing human heart Circulation 98 1998 1728 1734
12. S.C. Tyagi, S. Kumar, S.J. Voelker, H.K. Reddy, J.S. Janicki, J.J. Curtis Differential gene expression of extracellular components in dilated cardiomyopathy J Cell Biochem 63 1996 185 198
13. C.V. Thomas, M.L. Coker, J.L. Zellner, J.R. Handy, A. Jackson Crumbley Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated myocardium Circulation 97 1998 1708 1715
14. D.L. Mann, H. Taegtmeyer Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart Circulation 104 2001 1089 1091
15. K.T. Weber, P. Anversa, P.W. Armstrong, C.G. Brilla, J.C. Burnett, J.M. Cruickshank, R.B. Devereux, T.D. Giles, N. Korsgaard, C.V. Leier Remodeling and reparation of the cardiovascular system J Am Coll Cardiol 20 1992 3 16
16. P.A. Poole-Wilson Relation of pathophysiological mechanisms to outcome in heart failure J Am Coll Cardiol 22 1993 22A 29A
17. F.G. Spinale, M.L. Coker, B.R. Bond, J.L. Zellner Myocardial matrix degredation and metalloproteinase activation in the failing heart a potential therapeutic target Cardiovasc Res 46 2000 225 238
18. S. Tyagi Physiology and homeostasis of extracellular matrix cardiovascular adaptation and remodeling Pathophysiology 7 2000 177 182
19. H. Nagase Activation mechanisms of matrix metalloproteinases Biol Chem 378 1997 151 160
20. H. Senzaki, N. Paolocci, Y.A. Gluzband, M.L. Lindsey, J.S. Janicki, M.T. Crow, D.A. Kass B-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction Circ Res 86 2000 807 815
21. Y. Sakata, K. Yamamoto, T. Mano, N. Nishikawa, J. Yoshida, M. Hori, T. Miwa, T. Masuyama Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats its inhibition as a primary effect of angiotensin-converting enzyme inhibitor Circulation 109 2004 2143 2149
22. B. Schieffer, C. Bunte, J. Witte, K. Hoeper, R.H. Boger, E. Schwedhelm, H. Drexler Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease J Am Coll Cardiol 44 2004 362 368
23. B.I. Jugdutt Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways Curr Drug Target Cardiovasc Haematol Disord 3 2003 1 30
24. F. Zannad, F. Alla, B. Dousset, A. Perez, B. Pitt RALES Investigators Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure insights from the Randomized Aldactone Evaluation Study (RALES) Circulation 102 2000 2700 2706